NASDAQ:ARVN

Arvinas - ARVN Stock Forecast, Price & News

$42.80

-1.69 (-3.80%)

(As of 10/3/2022 12:00 AM ET)

Add

Compare

Today's Range: $41.67
▼
$45.18
50-Day Range: $41.87
▼
$57.99
52-Week Range: $34.90
▼
$97.33

Volume: 378,602 shs
Average Volume: 444,286 shs
Market Capitalization: $2.28 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $82.13

Arvinas MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.81 Rating Score
Upside/Downside: 91.9% Upside
$82.13 Price Target
Short Interest: Bearish
11.84% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.93
Based on 6 Articles This Week
Insider Trading: Selling Shares
$86,789 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($4.74) to ($5.60) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

525th out of 1,093 stocks

Pharmaceutical Preparations Industry

243rd out of 548 stocks

4.4

Analyst's Opinion

Consensus Rating
Arvinas has received a consensus rating of Buy. The company's average rating score is 2.81, and is based on 13 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $82.13, Arvinas has a forecasted upside of 91.9% from its current price of $42.80.
Amount of Analyst Coverage
Arvinas has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
11.84% of the float of Arvinas has been sold short.
Short Interest Ratio / Days to Cover
Arvinas has a short interest ratio ("days to cover") of 13.5, which indicates bearish sentiment.
Change versus previous month
Short interest in Arvinas has recently decreased by 1.09%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Arvinas does not currently pay a dividend.
Dividend Growth
Arvinas does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ARVN.

2.2

News and Social Media Coverage

News Sentiment
Arvinas has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Arvinas this week, compared to 3 articles on an average week.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Arvinas insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $86,789.00 in company stock.
Percentage Held by Insiders
Only 2.78% of the stock of Arvinas is held by insiders.
Percentage Held by Institutions
91.20% of the stock of Arvinas is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Arvinas are expected to decrease in the coming year, from ($4.74) to ($5.60) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Arvinas is -9.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Arvinas is -9.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Arvinas has a P/B Ratio of 2.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Arvinas (NASDAQ:ARVN) Stock

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

Receive ARVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter.

ARVN Stock News Headlines

October 3, 2022 | finance.yahoo.com

Arvinas Appoints Paul McInulty as Senior Vice President, Regulatory Affairs

September 30, 2022 | globenewswire.com

Arvinas Gives Back to Local Greater New Haven Community - GlobeNewswire

October 3, 2022 | Vantage Point (Ad)

How the Wealthy Elite are Picking Stocks

Grab your seat at our LIVE Training for traders. It’s your chance to learn how to pick the right stocks and find the market bottom. We’ll reveal 3 Tips for conquering volatility and a few under-the-radar stocks we believe have significant potential in the long run. Click here now to register.

September 30, 2022 | finance.yahoo.com

Arvinas Gives Back to Local Greater New Haven Community

September 29, 2022 | americanbankingnews.com

Arvinas, Inc. (NASDAQ:ARVN) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

September 26, 2022 | globenewswire.com

Arvinas to Present at Bank of America Securities Precision Oncology Conference - GlobeNewswire

September 26, 2022 | finance.yahoo.com

Arvinas to Present at Bank of America Securities Precision Oncology Conference

September 24, 2022 | americanbankingnews.com

Cantor Fitzgerald Comments on Arvinas, Inc.'s FY2022 Earnings (NASDAQ:ARVN)

October 3, 2022 | Vantage Point (Ad)

How the Wealthy Elite are Picking Stocks

September 23, 2022 | americanbankingnews.com

Arvinas (NASDAQ:ARVN) Stock Rating Reaffirmed by Cantor Fitzgerald

September 23, 2022 | americanbankingnews.com

Arvinas' (ARVN) "Overweight" Rating Reaffirmed at Cantor Fitzgerald

September 14, 2022 | streetinsider.com

Pardes Biosciences (PRDS) Appoints Laurie Smaldone Alsup and John C. Pottage to its Board - StreetInsider.com

September 13, 2022 | benzinga.com

Arvinas (NASDAQ:ARVN) – hC Bioscience Appoints Brad Margus to its Board of Directors - Benzinga

September 9, 2022 | benzinga.com

Arvinas (NASDAQ:ARVN) – Where Arvinas Stands With Analysts - Benzinga

September 9, 2022 | seekingalpha.com

ARVN stock initiated Overweight at Barclays on therapeutic platform (NASDAQ:ARVN) - Seeking Alpha

September 9, 2022 | benzinga.com

Arvinas (NASDAQ:ARVN) – Expert Ratings for Arvinas - Benzinga

August 28, 2022 | nasdaq.com

Investors in Arvinas (NASDAQ:ARVN) have made a decent return of 80% over the past three years

August 26, 2022 | nasdaq.com

Investors in Arvinas (NASDAQ:ARVN) have made a decent return of 80% over the past three years - Nasdaq

August 25, 2022 | seekingalpha.com

Arvinas Stock: Sports Unappealing Risk/Reward Profile (NASDAQ:ARVN) - Seeking Alpha

August 22, 2022 | benzinga.com

Arvinas's Return on Invested Capital Insights - Benzinga

August 19, 2022 | seekingalpha.com

Arvianas a buy at Piper Sandler following (failure of Sanofi breast cancer treatment - Seeking Alpha

August 18, 2022 | globenewswire.com

Arvinas Announces Changes to its Board of Directors - GlobeNewswire

August 18, 2022 | finance.yahoo.com

Arvinas Announces Changes to its Board of Directors

August 15, 2022 | globenewswire.com

Arvinas Appoints Lisa Sinclair as Senior Vice President, Corporate Operations - GlobeNewswire

August 15, 2022 | finance.yahoo.com

Arvinas Appoints Lisa Sinclair as Senior Vice President, Corporate Operations

August 8, 2022 | markets.businessinsider.com

8 Analysts Have This to Say About Arvinas

August 6, 2022 | seekingalpha.com

Arvinas GAAP EPS of $1.32 beats by $2.38, revenue of $31.3M beats by $7.59M (NASDAQ:ARVN) - Seeking Alpha

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ARVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter.

ARVN Company Calendar

Last Earnings: 8/04/2022
Today: 10/03/2022
Next Earnings (Estimated): 11/02/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ARVN
CUSIP: N/A
CIK: 1655759
Web: www.arvinas.com
Phone: (203) 535-1456
Fax: N/A
Employees: 280
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $82.13
High Stock Price Forecast: $115.00
Low Stock Price Forecast: $42.00
Forecasted Upside/Downside: +91.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.81
Research Coverage: 16 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.46)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-191,000,000.00
Net Margins: -255.97%
Pretax Margin: -247.24%
Return on Equity: -31.16%
Return on Assets: -15.33%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.78
Quick Ratio: 5.78

Sales & Book Value

Annual Sales: $46.70 million
Price / Sales: 48.76
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $14.78 per share
Price / Book: 2.90

Miscellaneous

Outstanding Shares: 53,205,000
Free Float: 51,726,000
Market Cap: $2.28 billion
Optionable: Not Optionable
Beta: 1.93

Key Executives

Dr. John G. Houston Ph.D. (Age 62)
CEO, Pres & Director
Comp: $1.07M

Mr. Sean A. Cassidy CPA (Age 52)
CPA, M.B.A., CFO & Treasurer
Comp: $667.73k

Dr. Ian Taylor Ph.D. (Age 59)
Chief Scientific Officer
Comp: $686.8k

Dr. Ronald A. Peck
Chief Medical Officer

Mr. Jeff Boyle
VP of Investor Relations

Mr. Matthew Batters J.D. (Age 46)
Gen. Counsel

Dr. Randy Teel Ph.D. (Age 43)
Sr. VP of Corp. & Bus. Devel.

Mr. Steve Weiss (Age 52)
Sr. VP & Chief HR Officer

Dr. John A. Grosso Ph.D. (Age 65)
Sr. VP of R&D Technical Operations

Ms. Angela M. Cacace Ph.D. (Age 54)
Sr. VP of Neuroscience & Platform Biology

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ARVN Stock - Frequently Asked Questions

Should I buy or sell Arvinas stock right now?: 16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 3 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ARVN shares.
View ARVN analyst ratings or view top-rated stocks.
What is Arvinas' stock price forecast for 2022?: 16 brokerages have issued 1-year price objectives for Arvinas' shares. Their ARVN share price forecasts range from $42.00 to $115.00. On average, they anticipate the company's stock price to reach $82.13 in the next twelve months. This suggests a possible upside of 93.8% from the stock's current price.
View analysts price targets for ARVN or view top-rated stocks among Wall Street analysts.
How have ARVN shares performed in 2022?: Arvinas' stock was trading at $82.14 at the beginning of the year. Since then, ARVN stock has decreased by 48.4% and is now trading at $42.39.
View the best growth stocks for 2022 here.
When is Arvinas' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our ARVN earnings forecast.
How were Arvinas' earnings last quarter?: Arvinas, Inc. (NASDAQ:ARVN) issued its quarterly earnings data on Thursday, August, 4th. The company reported ($1.32) earnings per share for the quarter, missing analysts' consensus estimates of ($1.02) by $0.30. The business earned $31.30 million during the quarter, compared to analysts' expectations of $23.71 million. Arvinas had a negative trailing twelve-month return on equity of 31.16% and a negative net margin of 255.97%. The company's revenue for the quarter was up 469.1% on a year-over-year basis. During the same period in the previous year, the business earned ($1.03) EPS.
What other stocks do shareholders of Arvinas own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD).

When did Arvinas IPO?: (ARVN) raised $100 million in an IPO on Thursday, September 27th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO.
What is Arvinas' stock symbol?: Arvinas trades on the NASDAQ under the ticker symbol "ARVN."
How do I buy shares of Arvinas?: Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Arvinas' stock price today?: One share of ARVN stock can currently be purchased for approximately $42.39.
How much money does Arvinas make?: Arvinas (NASDAQ:ARVN) has a market capitalization of $2.26 billion and generates $46.70 million in revenue each year. The company earns $-191,000,000.00 in net income (profit) each year or ($4.46) on an earnings per share basis.
How many employees does Arvinas have?: The company employs 280 workers across the globe.
How can I contact Arvinas?: Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The official website for the company is www.arvinas.com. The company can be reached via phone at (203) 535-1456 or via email at ir@arvinas.com.

This page (NASDAQ:ARVN) was last updated on 10/3/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Arvinas - ARVN Stock Forecast, Price & News

Arvinas MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month